Rockwell Medical (RMTI) Restructuring Costs (2018 - 2019)
Rockwell Medical (RMTI) posted Restructuring Costs of $430000.0 for Q2 2019, down 58.25% on a QoQ basis from $1.0 million in Q2 2018, and down 58.25% year-over-year from $1.0 million in Q2 2018.
Rockwell Medical (RMTI) Restructuring Costs (2018 - 2019) Analysis & Trends
Rockwell Medical's Restructuring Costs history runs 2 years deep, the most recent figure standing at $430000.0 for Q2 2019.
- Quarterly Restructuring Costs fell 58.25% year-over-year to $430000.0 in Q2 2019, while the trailing twelve-month figure through Jun 2020 was $430000.0 (down 70.55% YoY) and the FY2019 annual result came in at $430000.0, down 58.25% from the prior year.
- Restructuring Costs was $430000.0 for Q2 2019 at Rockwell Medical, down from $1.0 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $1.0 million in Q2 2018 and bottomed at $430000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Rockwell Medical | 26.61 Mn | 2.72 Mn | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 430,000.00 |
| Jun 30, 2018 | 1.03 Mn |